The Justice Department’s Fraud Division reported more than $1 billion in enforcement actions in a single week, the second consecutive week of results at that scale. The largest case centered on Brett Blackman, founder and owner of HealthSplash, who was convicted by a Southern District of Florida jury in a Medicare fraud conspiracy that billed over $1 billion and drew more than $450 million in payments. Separate actions during the same stretch included sentencing in a $522 million genetic-testing kickback scheme and charges tied to nearly $200 million in Medicare and CHAMPVA fraud, signaling that federal prosecutors are compressing major cases into rapid public cycles rather than spacing them across months.
Why back-to-back billion-dollar fraud weeks signal a strategic shift
Two straight weeks of billion-dollar enforcement totals are not a coincidence. The Fraud Division’s own framing treats these results as a deliberate display of throughput, with prosecutors securing trial convictions in schemes totaling over a billion dollars in the most recent seven-day window, according to a Justice Department announcement. A companion weekly summary described enforcement actions representing nearly $1 billion in fraud across additional cases, as detailed in a separate DOJ release. Stacking these announcements back to back suggests the division is prioritizing visible volume, bundling convictions, sentencings, and new charges into concentrated bursts that amplify deterrence messaging.
The broader context reinforces that reading. The 2026 National Health Care Fraud Takedown, a two-week operation, charged hundreds of defendants in connection with billions in alleged false claims and resulted in substantial asset seizures, according to the DOJ. That operation ran alongside the Fraud Section’s release of its Year in Review for 2025, which cataloged the section’s enforcement priorities and case statistics. Together, these moves point to a deliberate acceleration: prosecutors appear to be shortening the gap between indictment and public resolution, at least for showcase cases, while grouping smaller matters into weekly roundups that inflate headline totals and underscore the department’s nationwide reach.
For taxpayers, the stakes are direct. Medicare paid more than $450 million on false claims in the Blackman case alone. The genetic-testing scheme generated tens of millions in payments before sentencing. Every dollar paid out on fraudulent billing is a dollar drawn from a trust fund that covers roughly 67 million beneficiaries. Faster prosecution cycles could, in theory, cut off fraudulent payment streams sooner, but only if the speed does not come at the cost of weaker cases, thinner evidentiary records, or lighter sentences that fail to deter copycats.
Blackman conviction and genetic-testing sentencing anchor the billion-dollar count
The single largest contributor to the weekly total was the conviction of Brett Blackman, whose HealthSplash platform generated false durable medical equipment orders that billed Medicare over $1 billion and resulted in payments exceeding $450 million, according to a DOJ case summary. Blackman was found guilty by a Southern District of Florida jury. The case is notable not just for its size but for its mechanics: a software company, rather than a clinic or pharmacy, served as the engine for fraudulent prescriptions and orders, illustrating how digital intermediaries can scale billing fraud far beyond what a single bricks-and-mortar provider could manage.
Prosecutors said HealthSplash operated as a hub between telemarketing call centers, telemedicine providers, and suppliers of durable medical equipment. According to the government, marketers used aggressive outreach to steer Medicare beneficiaries into sham consultations, after which telemedicine practitioners approved high-reimbursement braces and other equipment with little or no legitimate medical basis. HealthSplash’s software allegedly automated and routed these orders to cooperating suppliers, who then billed Medicare. By sitting at the center of that network, the company could multiply each new marketing relationship into a stream of claims, turning relatively modest call-center operations into a billion-dollar conspiracy.
In the same reporting period, federal courts imposed sentences in a sprawling genetic-testing kickback scheme with a stated loss figure of $522 million. In that case, defendants were accused of paying illegal kickbacks to marketers and medical professionals to obtain DNA samples and signed test orders from Medicare beneficiaries, often through pop-up testing events or telehealth encounters. The tests, which prosecutors said were medically unnecessary for many patients, were then billed to Medicare at high rates. Payments of roughly $84 million flowed from those claims before the scheme was disrupted, underscoring how quickly niche technologies like cancer-genetic panels can be converted into mass-billing vehicles when oversight lags.
Additional charges during the same week targeted nearly $200 million in alleged fraud against Medicare and the Civilian Health and Medical Program of the Department of Veterans Affairs (CHAMPVA). Those cases, involving a mix of medical equipment, pharmacy benefits, and telehealth services, were smaller in isolation but important to the Justice Department’s message. By packaging them alongside the Blackman conviction and the genetic-testing sentencings, the Fraud Division could present a composite picture of systemic abuse across programs and regions, rather than a single outlier scandal.
Taken together, the back-to-back billion-dollar weeks amount to more than a statistical fluke. They mark an attempt by federal prosecutors to show that health care fraud enforcement can move at the same speed and scale as the schemes it targets. Whether that strategy ultimately reduces losses will depend on what follows: sustained resourcing for complex trials, continued focus on high-yield intermediaries like software platforms and telemarketing networks, and coordination with regulators and private insurers to detect suspicious billing earlier. For now, the Justice Department is signaling that it intends to keep compressing its biggest health care fraud cases into tightly choreographed bursts-and to make sure the public notices when it does.
David M. Keller is a finance writer based in Columbus, Ohio, covering personal finance and consumer-focused economic topics. He earned his degree in journalism from Ohio University and began his career reporting on local business and economic trends for a regional media outlet. Since then, he has contributed to a variety of online publications, focusing on clear, practical coverage of topics such as cost of living, debt, and everyday financial decision-making.
